Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra

Neuropsychopharmacology

Volumn 42, Issue 2, 2017, Pages 540-550

  Schoonover, Kirsten E ^a   McCollum, Lesley A ^b   Roberts, Rosalinda C ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 67; NEUROTRANSMITTER; TYROSINE 3 MONOOXYGENASE; VESICULAR GLUTAMATE TRANSPORTER; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2; 4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMIC ACID; SLC17A6 PROTEIN, HUMAN; SLC17A7 PROTEIN, HUMAN;

ADULT; ARTICLE; AUTOPSY; COMPARATIVE STUDY; CONTROLLED STUDY; DSM-III-R; DSM-IV; DSM-IV-TR; FEMALE; GABAERGIC TRANSMISSION; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; SCHIZOPHRENIA; SUBSTANTIA NIGRA; TREATMENT RESPONSE; WESTERN BLOTTING; BIOSYNTHESIS; CHEMISTRY; METABOLISM; MIDDLE AGED;

DOPAMINE; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1; VESICULAR GLUTAMATE TRANSPORT PROTEIN 2;

EID: 84988638002     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.164     Document Type: Article

References (59)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin R, Seibyl J, Bowers M et al (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761-767.
2. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR et al (1999). Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156: 1580-1589.
3. Bellocchio E, Reimer R, Fremeau R Jr, Edwards RH (2000). Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 289: 957-960.
4. Booze RM, Mactutus CF, Gutman CR, Davis JN (1993). Frequency analysis of catecholamine axonal morphology in human brain. J Neurol Sci 119: 99-109.
5. Breier A, Su T, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569-2574.
6. Carlsson A (1974). Antipsychotic drugs and catecholamine synapses. J Psychiatr Res 11: 57-64.
7. Carlsson A, Lindqvist M (1963). Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20: 140-144. []
8. Carlsson A, Winblad B (1976). Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 38: 271-276.
9. Centonze D, Picconi B, Baunez C, Borrelli E, Pisani A, Bernardi G et al (2002). Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors. Neuropsychopharmacology 26: 164-175.
10. Chertkow Y, Weinreb O, Youdim MB, Silver H (2007). Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. J Neural Transm (Vienna) 114: 1443-1454.
11. Cobb W, Abercrombie E (2002). Distinct roles for nigral GABA and glutamate receptors in the regulation of dendritic dopamine release under normal conditions and in response to systemic haloperidol. J Neurosci 22: 1407-1413.
12. Conley R, Kelly D (2001). Management of treatment resistance in schizophrenia. Biol Psychiatry 50: 898-911.
13. Creese I, Burt DR, Snyder SH (1976). Dopamine receptors and average clinical doses. Science 194: 546.
14. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999). The substantia nigra of the human brain. I: Nigrosome and the nigral matrix,compartmental organization based on calbindin D28K immunohistochemistry. Brain 122: 1421-1436.
15. Delay J, Deniker P, Harl JM, Grasset A (1952). N-dimethylaminoprophylchlorophenothiazine (4560 RP) therapy of confusional states. Ann Méd Psychol (Paris) 110: 398-403.
16. de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Stephano S, Favila R, Diaz-Galvis L et al (2013). Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 70: 1057-1066.
17. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J et al (2011). Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36: 1781-1791.
18. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD (2012). Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 169: 1203-1210.
19. Esclapez M, Tillakaratne NJ, Kaufman DL, Tobin AJ, Houser CR (1994). Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms. J Neurosci 14: 1834-1855.
20. Fallon J, Moore R (1978). Catecholamine innervation of the basal forebrain IV: topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol 180: 545-580.
21. Gaspar P, Stepniewska I, Kaas JH (1992). Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J Comp Neurol 325: 1-21.
22. Girault J, Spampinato U, Glowinski J, Besson MJ (1986). In vivo release of [3H]?-aminobutyric acid in the rat neostriatum-II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen. Neuroscience 9: 1109-1117.
23. Haber S, Fudge JL (1997). The primate substantia nigra and VTA: integrative circuitry and function. Crit Rev Neurobiol 11: 323-342.
24. Hadley J, Nenert R, Kraguljac NV, Bolding MS, White DM, Skidmore FM et al (2014). Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. Neuropsychopharmacology 39: 1020-1030.
25. Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K et al (2014). Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain 137: 2493-2508.
26. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M et al (1995). Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346: 1130-1131.
27. Howes O, Kapur S (2009). The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 35: 549-562.
28. Howes O, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK et al (2013). Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain 136: 3242-4251.
29. Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riderer P et al (1994). Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm Park Dis Dement Sect 8: 149-158.
30. Kane JM, Honigeld G, Singer J, Meltzer H (1988). Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24: 62-67.
31. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235-9249.
32. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS et al (1995). SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36: 1182-1190.
33. Lavoie B, Parent A (1990). Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 299: 1-16.
34. McCollum L, Walker CK, Roche JK, Roberts RC (2015). Elevated excitatory input to the nucleus accumbens in schizophrenia: a postmortem ultrastructural study. Schizophr Bull 41: 1123-1132.
35. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G (2002). Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5: 267-271.
36. Moghaddam B, Bunney B (1990). Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 755-760.
37. Mueller T, Haroutunian V, Davis KL, Meador-Woodruff JH (2004). Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Mol Brain Res 121: 60-69.
38. Nagatsu T, Levitt M, Udenfriend S (1964). Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239: 2910-2917.
39. Osborne P, O'Connor WT, Beck O, Ungerstedt U (1994). Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA, and acetylcholine release. Brain Res 634: 20-30.
40. Perez-Costas E, Melendez-Ferro M, Rice MW, Conley RR, Roberts RC (2012). Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra. Front Psychiatry 9: 31.
41. Perez-Costas E, Melendez-Ferro M, Roberts RC (2010). Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem 113: 287-302.
42. Phelps P, Alijani A, Tran T (1999). Ventrally located commissural neurons express the GABAergic phenotype in developing rat spinal cord. J Comp Neurol 409: 285-298.
43. Porrino L, Goldman-Rakic PS (1982). Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP. J Comp Neurol 205: 63-76.
44. Raju DV, Shah DJ, Wright TM, Hall RA, Smith Y (2006). Differential synaptology of vGluT2-containing thalamostriatal afferents between the patch and matrix compartments in rats. J Comp Neurol 499: 231-243.
45. Rice M, Roberts RC, Melendez-Ferro M, Perez-Costas E (2016). Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia. Brain Struct Funct 221: 185-201.
46. Roberts RC, Gaither LA, Gao XM, Kashyap SM, Tamminga CA (1995). Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse 20: 234-243.
47. Roberts R, Roche JK, Conley RR, Lahti AC (2009). Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse 63: 520-530.
48. Roberts RC, Roche JK, Somerville SM, Conley RR (2012) Ultrastructural distinctions between treatment responders and non-responders in schizophrenia: postmortem studies of the striatum. In:Labate L (ed). Mental Illnesses-Evaluation, Treatments and Implications. InTech: Croatia. pp 261-286.
49. Schoonover KS, McCollum LA, Roberts RC (2015). Tyrosine hydroxylase, GAD67, vGLUT1, and vGLUT2 proteins in the substantia nigra in schizophrenia. Poster presented at the Society for Neuroscience annual meeting, Chicago, IL.
50. Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R et al (2015). Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 72: 316-324.
51. Spokes E, Garrett NJ, Rossor MN, Iverson LL (1980). Distribution of GABA in post-mortem brain tissue from control, psychotic, and Huntington's chorea subjects. J Neurol Sci 48: 303-313.
52. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ et al (2006). Human postmortem tissue: what quality markers matter? Brain Res 1123: 1-11.
53. Storm-Mathisen J (1974). GABA as a transmitter in the central nervous system of vertebrates. J Neural Transm 11: 227-253.
54. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H et al (1988). Neurotransmitters, receptors, and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78: 121-137.
55. Watanabe Y, Tanaka A, Tsukabe A, Kunitomi Y, Nishizawa M, Hashimoto R et al (2014). Neuromelanin magnetic resonance imaging reveals increased dopaminergic neuron activity in the substantia nigra of patients with schizophrenia. PLoS One 9: e104619.
56. White DM, Kraguljac NV, Reid MA, Lahti AC (2015). Contribution of substantia nigra glutamate to prediction error signals in schizophrenia: a combined magnetic resonance spectroscopy/functional imaging study. NPJ Schizophr 1: 14001.
57. Williams SM, Goldman-Rakic PS (1998). Widespread origin of the primate mesofrontal dopamine system. Cereb Cortex 8: 321-345.
58. Yoon JH, Minzenberg MJ, Raouf S, D'Esposito M, Carter CS (2013). Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol Psychiatry 74: 122-129.
59. Yoon JH, Westphal AJ, Minzenberg MJ, Niendam T, Ragland D, Lesh T et al (2014). Task-evoked substantia nigra associated with prefrontal hypofunction, prefrontonigral disconnectivity and nigrostriatal connectivity predicting psychosis severity in medication naïve first episode schizophrenia. Schizophr Res 159: 521-526.